

Natera collaborates with Fox Chase

October 2018—Natera announced it has partnered with Fox Chase Cancer Center to assess the Signatera (RUO) ctDNA assay for recurrence monitoring of kidney cancer. The study will analyze biological specimens collected and banked from 49 patients diagnosed with kidney cancer, including a group whose cancer recurred and a group that did not recur after three years or more. The study will use Natera's proprietary customized assay and NGS-based technology to determine whether Signatera can be used to distinguish between the recurring and nonrecurring kidney cancer cases.

[Natera](#), 844-778-4700